retatrutide update Eli Lilly’s Phase 3 data is in on Retatrutide! Here’s what they found This weight-loss drug hasn't been

The LS-mean reduction in HbA1c in the high GLP-1 was significantly greater than in the low GLP-1 groups by -0.58% (95% CI -1.04, -0.12%)

When clinically appropriate, adjunctive therapiesincluding GLP-1based medicationsmay be incorporated as part of a structured, medically supervised plan

And for most, it works

02 Review Your Care Pathway Review your comprehensive pathway

Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation

Frequently Asked Questions As of July 2026, retatrutide has completed four Phase 3 readouts: TRIUMPH-4 (28.7% weight loss in knee OA population, December 2025), TRIUMPH-1 (28.3% weight loss in 2,339 general obesity patients, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c and 16.8% weight loss in 537 T2D patients, June 2026), and the TRIUMPH-1 sleep apnea substudy (60.6% AHI reduction, June 2026)